CSF1R and central nervous system cancer: In mice bearing glioblastoma multiforme or patient-derived glioma, BLZ945, a brain-penetrant kinase inhibitor targeting CSF-1R depolarizes M2 phenotype of TAMs, impairs their pro-tumor function and slows tumor growth that is associated with decreased M2 gene signatures [174].